COVID-19 额外基础剂次或加强剂次疫苗在预防养老院居民 SARS-CoV-2 感染中的效果——奥密克戎变异株广泛流行期间,美国,2022年2月14日至3月27日
分析2022年2月14日至3月27日美国养老院居民每周COVID-19监测与疫苗接种数据,此时奥密克戎变异株占测序分离株>99%。调整日历周和技能护理机构间变异后,额外基础剂次或加强剂次疫苗相对于仅基础免疫接种的感染相对疫苗有效性为46.9%(95%CI=44.8%-48.9%)。结果表明养老院居民接种额外基础剂次或加强剂次对奥密克戎变异株感染的保护优于仅基础免疫接种。
要点
- 调整日历周和机构间变异后,额外基础剂次或加强剂次相对疫苗有效性为46.9%(95%CI=44.8%-48.9%)。
- 养老院居民接种额外基础剂次或加强剂次对奥密克戎感染的保护优于仅基础免疫接种。
- 所有免疫功能低下的养老院居民应接种额外基础剂次,所有养老院居民符合条件时应接种加强剂次。
核心结论
- 养老院居民中,COVID-19额外基础剂次或加强剂次对奥密克戎变异株感染提供的保护优于仅基础免疫接种。
- 所有免疫功能低下的养老院居民应接种额外基础剂次,所有养老院居民符合条件时应接种加强剂次以预防COVID-19。
研究设计与样本
- 分析2022年2月14日至3月27日技能护理机构向CDC国家医疗安全网络报告的养老院居民每周COVID-19监测和疫苗接种覆盖率数据,此时奥密克戎变异株占测序分离株>99%。
- 估计任何COVID-19额外基础剂次或加强剂次相对于基础免疫接种的感染相对疫苗有效性,调整日历周和技能护理机构间变异。
主要发现
- 调整日历周和技能护理机构间变异后,COVID-19额外基础剂次或加强剂次相对于基础免疫接种的感染相对疫苗有效性为46.9%(95%CI=44.8%-48.9%)。
关键数值与推荐
- 基础免疫接种定义为接种2剂mRNA疫苗(BNT162b2[辉瑞-BioNTech]或mRNA-1273[莫德纳])或1剂Ad26.COV2(强生[Janssen])疫苗。
- CDC建议所有年龄≥12岁者接种COVID-19加强剂次疫苗。
- 中度至重度免疫功能低下者(包括许多养老院居民)也被建议接种额外基础剂次COVID-19疫苗。
临床怎么用
- 所有免疫功能低下的养老院居民应接种额外基础剂次,所有养老院居民符合条件时应接种加强剂次以预防COVID-19。
- 应结合其他COVID-19预防策略(包括对养老院工作人员和访客进行检测和接种疫苗)实施使养老院居民及时接种疫苗的努力。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nursing home residents have experienced disproportionally high levels of COVID-19-associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1). Following reported declines in vaccine-induced immunity after primary series vaccination, defined as receipt of 2 primary doses of an mRNA vaccine (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) or 1 primary dose of Ad26.COV2 (Johnson & Johnson [Janssen]) vaccine (2), CDC recommended that all persons aged ≥12 years receive a COVID-19 booster vaccine dose.* Moderately to severely immunocompromised persons, a group that includes many nursing home residents, are also recommended to receive an additional primary COVID-19 vaccine dose.† Data on vaccine effectiveness (VE) of an additional primary or booster dose against infection with SARS-CoV-2 (the virus that causes COVID-19) among nursing home residents are limited, especially against the highly transmissible B.1.1.529 and BA.2 (Omicron) variants. Weekly COVID-19 surveillance and vaccination coverage data among nursing home residents, reported by skilled nursing facilities (SNFs) to CDC's National Healthcare Safety Network (NHSN)§ during February 14-March 27, 2022, when the Omicron variant accounted for >99% of sequenced isolates, were analyzed to estimate relative VE against infection for any COVID-19 additional primary or booster dose compared with primary series vaccination. After adjusting for calendar week and variability across SNFs, relative VE of a COVID-19 additional primary or booster dose was 46.9% (95% CI = 44.8%-48.9%). These findings indicate that among nursing home residents, COVID-19 additional primary or booster doses provide greater protection against Omicron variant infection than does primary series vaccination alone. All immunocompromised nursing home residents should receive an additional primary dose, and all nursing home residents should receive a booster dose, when eligible, to protect against COVID-19. Efforts to keep nursing home residents up to date with vaccination should be implemented in conjunction with other COVID-19 prevention strategies, including testing and vaccination of nursing home staff members and visitors.
引用
- Prasad N, Derado G, Nanduri SA, et al. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35511708. doi:10.15585/mmwr.mm7118a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。